glucagen hypokit 1mg powder and solvent for solution for injection
imported - glucagon hydrochloride - powder and solvent for solution for injection - 1mg
baqsimi nasal powder 3 mg (バクスミー点鼻粉末剤3mg)
eli lilly japan k.k - glucagon - white powder for intranasal application
sandostatin 0.1 mgml
novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
sandostatin 0.05 mgml
novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
sandostatin 0.5 mg1ml
novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
sandostatin lar
novartis new zealand ltd - octreotide acetate 11.2mg equivalent to octreotide 10 mg; - powder for injection - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas
sandostatin lar
novartis new zealand ltd - octreotide acetate 22.4mg equivalent to octreotide 20 mg; - powder for injection - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas
sandostatin lar
novartis new zealand ltd - octreotide acetate 33.6mg equivalent to octreotide 30 mg; - powder for injection - 30 mg - active: octreotide acetate 33.6mg equivalent to octreotide 30 mg excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas
octreotide depot
teva pharma (new zealand) limited - octreotide acetate 11.2mg equivalent to octreotide 10 mg; - powder for injection with diluent - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
octreotide depot
teva pharma (new zealand) limited - octreotide acetate 22.4mg equivalent to octreotide 20 mg; - powder for injection with diluent - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.